Skip to main content

Table 1 Demographics, baseline characteristics and medical history of patients enrolled in the ERICA trial[4]

From: Impact of angina frequency on health utility values of patients with chronic stable angina

Characteristics

Placebo + Amlodipine (n = 283)

Ranolazine + Amlodipine (n = 281)

Age (years), mean ± SD

61.3 ± 9.0

62.0 ± 8.7

Gender (M/W),%

73/27

72/28

Race,%

  

White

99

98

Black

1

1

Asian

0

<1

Geographic region,%

  

Eastern Europe

97

97

North America

3

3

Concomitant use of LANs,%

43

46

Weekly rate of angina attacks,trimmed mean ± SE

5.68 ± 0.26 (n = 281)

5.59 ± 0.21 (n = 277)

Weekly rate of NTG consumption, trimmed mean ± SE

5.02 ± 0.33 (n = 281)

4.43 ± 0.26 (n = 277)

SAQ score, mean ± SD

  

Angina frequency

40.0 ± 14.9 (n = 281)

40.6 ± 13.2 (n = 277)

Physical limitation

48.9 ± 17.3 (n = 276)

49.2 ± 17.4 (n = 271)

Anginal stability

57.2 ± 17.7 (n = 281)

54.7 ± 18.0 (n = 277)

Disease perception

41.5 ± 17.8 (n = 281)

41.6 ± 17.2 (n = 277)

Treatment satisfaction

75.4 ± 14.0 (n = 281)

74.6 ± 14.3 (n = 277)

History of unstable angina,%

98 (35)

100 (36)

History of CHF,%

145 (51)

146 (52)

NYHA functional class I

38 (13)

32 (11)

NYHA functional class II

86 (30)

99 (35)

NYHA functional class III

21 (7)

15 (5)

NYHA functional class IV

0

0

Diabetes mellitus,%

54 (19)

52 (19)

Insulin-dependent

2 (1)

11 (4)

Previous myocardial infarction,%

233 (82)

218 (78)

Previous CABG,%

34 (12)

28 (10)

Previous PCI

25 (9)

34 (12)

Intermittent claudication,%

32 (11)

39 (14)

Hypertension,%

257 (91)

246 (88)

  1. CABG = Coronary Artery Bypass Grafting; CHF = Congestive Heart Failure; ERICA = Efficacy of Ranolazine in Chronic Angina; LAN = long-acting nitrate; NTG = nitroglycerin; NYHA = New York Heart Association; PCI = Percutaneous Coronary Intervention; SAQ = Seattle Angina Questionnaire; SD = standard deviation; SE = standard error.